Multicenter clinical study on Fuzhenghuayu capsule against liver fibrosis due to chronic hepatitis B

Table 14 Changes in liver function of two groups before and after treatment (mean±SD).

Parameter	Group	Pretreatment	6 wk of treatment	12 wk of treatment	18 wk of treatment	24 wk of treatment
Alb (g/L)	Experimental	40.1±5.2	42.6±5.0b	43.2±4.7b	43.3±4.3bc	43.5±5.7bc
	Control	41.0±5.9	42.6±5.3b	43.3±5.3b	42.8±4.9b	43.1±5.2b
Glo (g/L)	Experimental	30.1±6.4	29.8±6.1	30.8±6.5	31.3±5.7	31.3±5.8
	Control	29.2±5.1	30.9±5.7b	30.9±6.0a	31.9±5.6b	31.9±6.6b
ALT (U/L)	Experimental	116.0±74.6	57.5±56.0bc	50.9±39.0bc	50.1±43.6bc	49.4±41.2bc
	Control	96.7±55.0	59.5±52.0b	58.9±54.4b	61.8±58.5b	51.2±39.0b
AST (U/L)	Experimental	78.4±59.3	55.5±47.7b	54.2±47.4b	46.2±29.2bc	48.2±35.0b
	Control	68.5±53.1	53.8±39.1b	59.3±50.2a	55.8±39.4a	51.9±51.6b
GGT (U/L)	Experimental	92.0±71.4	75.3±64.9b	67.9±75.8b	67.4±70.1b	56.4±51.8bd
	Control	86.8±68.6	68.6±52.9b	67.7±59.9b	70.4±48.0a	67.3±58. 2b
ALP (U/L)	Experimental	100.6±38.2	96.4±47.3a	100.3±52.2	97.9±47.1	93.5±38.8a
	Control	95.1±41.9	97.0±43.6	93.1±42.1	91.1±36.5	92.9±41.5
TBil (mmol/L)	Experimental	17.8±7.9	15.8±5.9b	15.9±6.4b	15.5±9.5bc	15.5±5.8bc
	Control	16.9±8.4	16.4±8.2	17.1±8.6	18.5±12.1	18.5±13.5
DBil (mmol/L)	Experimental	5.9±5.5	4.7±3.0b	4.6±3.0bc	4.5±2.5bc	4.6±2.7bd
	Control	5.2±4.4	4.8±3.7	5.1±3.7	5.3±3.6	5.9±5.4

^aP<0.05,

^bP<0.01 vs the same group;

^cP<0.05,

^dP<0.01 vs difference between different time points value and previous treatment in two groups.